Effect of biological therapy on work participation in patients with ankylosing spondylitis: a systematic review
- 1 December 2012
- journal article
- review article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 71 (12) , 1924-1933
Abstract
Objectives To review systematically the effect of biological treatment in patients with ankylosing spondylitis (AS) on three work outcomes: work status, absence from paid work and at-work productivity. Methods A systematic literature search was performed (Pubmed, Embase, Cochrane Library) to identify relevant articles. Risk of bias of included studies was assessed using the Cochrane guidelines for cohorts and randomised controlled trials (RCTs). Data were extracted using a self-composed data extraction form. Owing to extensive interstudy heterogeneity, narrative summaries were used to present the data. Results Nine studies were included (six uncontrolled cohorts, one population-controlled cohort and two RCTs) that reported on 39 comparisons. Overall, 961 patients were treated with three different tumour necrosis factor α inhibitors (etanercept, infliximab, adalimumab). For presenteeism and absence from work, most comparisons showed improvement in favour of biological agents, but not all comparisons were statistically significant and they usually concerned before–after analyses. For work status, changes were less often positive, but studies dealt with patients with longstanding AS, lacked power and had a relatively short follow-up. Conclusions Although trends towards beneficial effects of biological agents in longstanding AS were seen on all work outcomes, the methodological limitations in the studies included hampers clear conclusions. Since the majority of studies were (extensions of) controlled trials, the generalisability of the effect of biological agents on work participation in real life should be further studied in larger (population-controlled) studies. The effect of biological agents in patients with early disease has not yet been examined.Keywords
This publication has 19 references indexed in Scilit:
- Methodological issues when measuring paid productivity loss in patients with arthritis using biologic therapies: an overview of the literatureRheumatology, 2012
- Reduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countriesRheumatology, 2011
- Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort studyRheumatology, 2011
- Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics RegisterRheumatology, 2010
- Work Status Among Patients With Ankylosing Spondylitis in ArgentinaJCR: Journal of Clinical Rheumatology, 2008
- Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitisRheumatology, 2007
- Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: Results from a randomized, placebo‐controlled trialArthritis Care & Research, 2006
- Using the World Health Organization Health and Work Performance Questionnaire (HPQ) to Evaluate the Indirect Workplace Costs of IllnessJournal of Occupational and Environmental Medicine, 2004
- Ankylosing spondylitis: what is the cost to society, and can it be reduced?Best Practice & Research Clinical Rheumatology, 2002
- The Work Limitations QuestionnaireMedical Care, 2001